Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Statement re possible offer

18 Jul 2008 07:00

RNS Number : 3584Z
Angle PLC
18 July 2008
 



For Immediate Release

18 July 2008

ANGLE plc ("ANGLE" or "the Company")

Statement re possible offer - Termination of talks

Further to the announcement made by Braveheart Investment Group plc ("Braveheart") on 11 July 2008 ("the Braveheart Announcement") and the subsequent announcement made by the Company on the same day, ANGLE sets out its response to the Braveheart Announcement below:

Braveheart approached ANGLE last year with a possible offer, which was rejected. At that time, Braveheart was unable to convince the ANGLE Board that the relative valuations placed on the companies were appropriate or that there were synergies between the businesses that would add sufficient value. On 7 April 2008, the Company announced that it had received a possible offer of 60 pence for each ANGLE ordinary share and that the consideration would be satisfied in full by the issue of new ordinary shares in the acquiring company. 
On 9 April 2008, Braveheart announced that it was considering making a recommended offer for the entire issued and to be issued share capital of ANGLE, with non-binding letters of intent to support a recommended offer from certain institutional investors representing, according to Braveheart, 35.76 per cent of ANGLE's issued shares. The Board of ANGLE was aware, however, that other substantial shareholders were not in favour of the Braveheart possible offer and was obliged to consider the interests of shareholders as a whole.
The Board of ANGLE noted that the approach was at a significant premium to the ANGLE share price but that the consideration would be entirely in new Braveheart shares. In subsequent discussions, Braveheart stated that a cash element to the possible offer was not available. 
Given the proposed premium and the views of certain of ANGLE's shareholders, this possible offer has received considerable attention from the ANGLE Board who fully recognise their responsibilities to all stakeholders, including that of maximising shareholder value. 
Braveheart shares, like those of ANGLE, are not very liquid and this has led the ANGLE Board to focus on how longer term value might be created. A key consideration was the ability of Braveheart to help release the potentially significant value inherent in the ANGLE portfolio of companies, which would otherwise accrue solely to the benefit of ANGLE's shareholders. In this regard, ANGLE noted that Braveheart's business consists principally of arranging third party investment syndicates in Scotland including private investors, Government and other co-investors to invest in, to date, predominantly Scottish companies in which Braveheart makes a small minority investment. ANGLE's business model centres around an international Management services business and a portfolio of companies, which it has founded and developed and in which it holds a controlling or substantial shareholding. These portfolio companies are based both in the USA, where the Board believes that Braveheart has no direct experience or capability, and in England.
During the last financial year, ANGLE continued to invest in its portfolio companies, and including amounts received from third parties, £4.5 million was raised. In the present business climate, however, it is difficult to attract third party funding for developing technology companies and cash generation and conservation are important. As ANGLE has made clear to its shareholders in its recent results, it has been taking active steps to develop its portfolio companies so their calls on ANGLE's own funds are reduced. Significant progress has been made in this direction but the Board would, nonetheless, see value in a transaction which gave access to significant additional funds for the existing ANGLE portfolio, in order to accelerate its development. The ANGLE Board believes, however, that its portfolio is progressing under its current funding arrangements.
Braveheart has confirmed to ANGLE on a number of occasions that its existing cash resources would not be made available to any significant extent for investment into the ANGLE portfolio but that it would seek third party investment to provide this funding. The ANGLE Board believes that Braveheart has little or no experience of raising funding for companies based in the USA and is less able to leverage its partners for investments outside of Scotland. The ANGLE Board believes that the Enterprise Investment Scheme (EIS) and the facility provided by the Scottish co-investment funds that Braveheart has used in arranging deals in Scotland, would not be available for companies based in the USA.
Given the poor performance of Braveheart's share price since its IPO in March 2007, and the ANGLE Board's doubts as to whether Braveheart's largely local, minority investment business approach would offer any benefits to ANGLE's international activities (including ANGLE's Management services business which would be entirely new to Braveheart), the ANGLE Board could see little merit in the possible offer unless Braveheart could convince the ANGLE Board that significant funding will be made available to accelerate the growth of the ANGLE portfolio sufficiently to compensate ANGLE shareholders for the dilutive effects of the possible offer. To that end, and contrary to the statement made in the Braveheart Announcement regarding the supply of information, ANGLE supplied Braveheart with detailed unpublished information on the ANGLE portfolio companies and its Management services business, and the ANGLE Board believes it has responded to all of Braveheart's information requests in relation to that information. The ANGLE Board has consistently and repeatedly sought written comfort from Braveheart that additional funding would be available to the ANGLE portfolio following completion of a Braveheart possible offer for ANGLE in order for the ANGLE Board to consider recommending the Braveheart possible offer to ANGLE shareholders. No comfort has been provided by Braveheart to date which is sufficient to provide the ANGLE Board with the level of certainty that it requires that such funding would be available. Notwithstanding the above, and in order to try to progress discussions, ANGLE indicated to Braveheart, initially on 13 June 2008, that it was prepared to enter into exclusivity with Braveheart on the condition that comfort on funding would be provided prior to a recommendation being sought from the ANGLE Board. This was made clear again to Braveheart in a letter sent on 1 July 2008, to which no response was received prior to the Braveheart Announcement on 11 July 2008. Whilst the ANGLE share price performance has been very disappointing, the Company is profitable, cash generative at the operating level and, as a result of their maturing profile and due to management actions taken over the last 12 months, there is a reduced demand on ANGLE's cash for its portfolio companies. As announced on 10 July 2008, ANGLE reported pre-tax profits (before controlled investments) for the financial year ended 30 April 2008 of £3.4 million on sales of £3.9 million for the year ended 30 April 2008. As at 30 April 2008, Net Asset Value was £7.2 million, excluding the value of controlled investments, into which ANGLE has invested £3.7 million. As announced on 25 June 2008, Braveheart reported a pre-tax profit for the financial year ended 31 March 2008 of £0.1m on revenue of £0.7m. As at 31 March 2008, Net Asset Value was £7.3 million and Braveheart had no controlled investments.
The ANGLE Board has continuing concerns with regard to relative valuations and the lack of synergy between its business and that of Braveheart. The ANGLE Board considers that there is little or no evidence to suggest that Braveheart can add significant value to the ANGLE portfolio or contribute significantly to the Management services business.

After careful consideration of the issues and of the interests of ANGLE shareholders as a whole, the Board of ANGLE has unanimously concluded that the Braveheart possible offer is not in the interests of ANGLE shareholders as a whole. Accordingly, ANGLE is discontinuing all discussions with Braveheart and is looking forward to focusing its attention exclusively on running the ANGLE business and seeking to maximise shareholder value in these difficult market conditions.

This announcement is not being made with the agreement or approval of Braveheart.

18 July 2008

Enquiries:

ANGLE plc

01483 295830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Mark Connelly, Stewart Wallace

0207 523 8350

Buchanan Communications

Suzanne Brocks, James Strong

0207 466 5000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPBCGDRSXBGGIR
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.